Anaptysbio (ANAB) Other Non Operating Income (2016 - 2026)
Anaptysbio's (ANAB) quarterly Other Non Operating Income came in at -$1000.0 in Q1 2026, down 100.05% YoY from $1.9 million in Q1 2025, and up 66.67% on a QoQ basis from -$3000.0 in Q4 2025.
Powered by 
Analysis
Anaptysbio (ANAB) Other Non Operating Income (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Other Non Operating Income data on file, last reported at -$1000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 100.05% year-over-year to -$1000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 83.89% YoY) and the FY2025 annual result came in at $5.4 million, up 38685.71% from the prior year.
- Other Non Operating Income rose to -$1000.0 in Q1 2026, from -$3000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $3.5 million in Q2 2025 to a low of -$5000.0 in Q3 2024.
- A 5-year average of $553000.0 and a median of $3000.0 in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2024 — Other Non Operating Income tumbled 600.0% — and 2025, when it soared 95200.0%.
- Tracing ANAB's Other Non Operating Income over 5 years: stood at -$4000.0 in 2022, then jumped by 71100.0% to $2.8 million in 2023, then slumped by 99.26% to $21000.0 in 2024, then slumped by 114.29% to -$3000.0 in 2025, then soared by 66.67% to -$1000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$1000.0 (Q1 2026), -$3000.0 (Q4 2025), and $3.5 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Anaptysbio | 1.62 Bn | 1.33 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1,000.00 |
| Dec 31, 2025 | -3,000.00 |
| Jun 30, 2025 | 3.53 Mn |
| Mar 31, 2025 | 1.90 Mn |
| Dec 31, 2024 | 7.06 Mn |
| Sep 30, 2024 | -5,000.00 |
| Mar 31, 2024 | -2,000.00 |
| Dec 31, 2023 | 6.21 Mn |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 3,000.00 |
| Mar 31, 2023 | -4,000.00 |
| Dec 31, 2022 | -4,000.00 |
| Sep 30, 2022 | 4,000.00 |
| Jun 30, 2022 | 6,000.00 |
| Mar 31, 2022 | 6,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Sep 30, 2021 | 33,000.00 |
| Mar 31, 2021 | 3,000.00 |
| Dec 31, 2020 | -75,000.00 |
| Sep 30, 2020 | -56,000.00 |